U

University of Minnesota | Pediatric Endocrinology Department

Research site
(Unclaimed)
Location
515 Delaware St SE, Office 13-160, Minneapolis, Minnesota, United States of America
Site insights

Parent organization

This site is a part of University of Minnesota

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

28 of 227
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

This is a Phase 2, randomized, open-label, 24-week treatment study to evaluate the potential pharmacodynamic (PD) activity, safety, tolerability, and...

Enrolling
Pmm2-CDG
Drug: GLM101

This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety a...

Enrolling
Multifocal Motor Neuropathy (MMN)
Biological: ARGX-117
Other: Placebo

This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.

Enrolling
Age Related Macular Degeneration
Drug: HLX04-O
Drug: ranibizumab

This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight i...

Enrolling
Obesity
Drug: Semaglutide
Drug: Placebo

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Enrolling
Neoplasm Metastasis
Drug: Trastuzumab
Drug: Pertuzumab

This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation,optimization, and expansion study of tegavivint in...

Enrolling
Advanced Hepatocellular Carcinoma
Drug: Pembrolizumab
Drug: Tegavivint

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional,...

Enrolling
Head and Neck Cancer
Combination Product: ASP-1929 Photoimmunotherapy
Drug: Physician's Choice SOC

This is a prospective, multi-center, randomized, controlled, patient- and evaluator-blinded study comparing treatment with the CardiAMP cell therapy...

Active, not recruiting
Heart Failure, Systolic
Other: Sham
Biological: Autologous cell therapy

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Rest...

Enrolling
Dilated Cardiomyopathy
Heart Failure With Reduced Ejection Fraction (HFrEF)
Device: AccuCinch Ventricular Restoration System
Drug: Guideline-Directed Medical Therapy

The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious pu...

Enrolling
Puberty; Precocious, Central
Drug: Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide

PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointe...

Enrolling
Gastrointestinal Complication
Device: PrevisEA device

First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion...

Active, not recruiting
Non Small Cell Lung Cancer Metastatic
Platinum Resistant Ovarian Cancer
Drug: upifitamab rilsodotin

The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtyp...

Active, not recruiting
Fanconi Anemia Complementation Group A
Biological: RP-L102

The purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surger...

Enrolling
Recurrent Brain Metastases
Procedure: Craniotomy
Radiation: Cesium-131 brachytherapy

Prospective, multi-center, single-arm, seamless phase-pivotal study conducted in participants diagnosed with UUI who have failed or could not tolerat...

Active, not recruiting
Urinary Urgency Incontinence
Device: Neuspera Implantable Sacral Nerve Stimulation System

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Explora...

Enrolling
Muscular Dystrophy, Landouzy Dejerine
Fascioscapulohumeral Muscular Dystrophy
Drug: AOC 1020
Drug: Placebo

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with adva...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: MRTX849
Drug: Afatinib

Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circu...

Enrolling
Focal Segmental Glomerulosclerosis
Device: LIPOSORBER® LA-15 System

This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus...

Enrolling
Brain Metastases
Radiation: Stereotactic Radiation Therapy
Device: Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)

This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiot...

Active, not recruiting
Focal Segmental Glomerulosclerosis
Drug: Irbesartan
Drug: RE-021 (Sparsentan)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems